DOCK11

Across TCGA pan-cancer cohorts, DOCK11 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated DOCK11 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher DOCK11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DOCK11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

KIRC, SARC, and BRCA are the cancer types where DOCK11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	24	view →
SARC	OS	Median	All	0.022	0.861	<.001	12	view →
BRCA	OS	Median	IV	0.106	0.791	<.001	12	view →
READ	OS	Median	III,IV	0.644	0.932	<.001	8	view →
PRAD	DFS	Median	All	0.504	0.936	<.001	6	view →
UCEC	DFS	Median	All	0.782	0.621	.013	4	view →
ESCA	OS	Median	All	0.429	0.705	.039	3	view →
STAD	DFS	Median	All	0.844	0.388	.040	3	view →
LUAD	OS	Median	III,IV	0.322	0.664	.043	3	view →
COAD	DFS	Median	II,III,IV	0.896	0.646	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

DOCK11–KIRC (DFS)

Open the KIRC breakdown →